Novartis Investor Presentation
Leadership across 3 next-generation technology platforms...
2. Technology platforms
New Novartis: Our strategy
Our focus
Core Therapeutic Areas
> Technology platforms
Priority geographies
Capital allocation / structure
Our priorities
Conclusion
Abbreviations
Shift towards biologics and advanced
technology platforms
Proportion % of IM sales by platform
Outlook illustrative
Leadership across 3 next-generation
technology platforms
Gene & Cell therapy
5%
22%
73%
2020
Small molecules
Biologics
RLT
XRNA¹
Gene
Cell
Expand
platforms
Existing
commercial
assets
zolgensma®
>KYMRIAH
LUTATHERAⓇ
LEQVIO®
LUXTURNA
PLUVICTO™
Scale
biologics
Focus on new approaches
to address previously
intractable targets (e.g. TPD)
2030
3 next-generation
technology platforms
Key focus
Novel cargos,
Next
targeting &
switchable
expression
generation of
CAR-Ts &
manufacturing
efficiency
Additional
solid tumors
Build up siRNA
capabilities &
explore new
approaches
in RNA
# of projects²
19
14
9
11
Expected
next filing
2025
2025
2023
2025
1. XRNA includes RNA targeting LMWS, ASOS, siRNA, mRNA cancer vaccines 2. Exploratory to Ph1/2 (July 2022)
10
Novartis Investor Presentation | September 22, 2022
U |
NOVARTIS | Reimagining MedicineView entire presentation